Financial statements Synoptis Pharma
Cash flow statement of Synoptis Pharma
Company age:
Age:
20 y. 11 m. 27 d.
Share capital:
Share capital:
50 000 PLN
Cash inflows of SYNOPTIS PHARMA
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Net cash from operating expenses | 37 725 200,59 | 26 959 061,10 | 26 773 156,75 | 36 593 479,08 | 29 720 605,46 | 45 135 523,45 |
| Net cash flow from investing activities | -2 052 163,89 | 14 276 350,60 | 48 077 981,44 | 12 065 194,94 | -3 650 511,93 | 2 983 115,21 |
| Net cash flow from financial activities | -35 652 084,62 | -41 186 897,50 | -75 000 000,00 | -48 435 927,12 | -26 013 107,30 | -48 014 223,57 |
| Total net cash flow | 20 952,08 | 48 514,20 | -148 861,81 | 222 746,90 | 56 986,23 | 104 415,09 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.